ASSOCIATION OF THE METABOLIC SYNDROME CONSTITUENTS WITH MARKERS OF SUBCLINICAL TARGET ORGAN DAMAGE DURING FOLLOW-UP OF INTELLECTUAL LABORERS

Aim. To evaluate the relation of metabolic syndrome (MS) and its constituents with markers of subclinical damage of target organs (TOD) in follow-up of almost healthy intellectual laborers.

Material and methods. From the selection of 1600 employees of a bank we randomly selected 383 with at least one component of MS without cardiovascular disorders, of those by the end of 2 years period 331 came to final visit (response 86%). Mean age 46,6±9,0 y., mostly women (214 (64,6%)). All patients underwent anthropometry, blood pressure measurement (BP), lipids investigation, creatinine and fasting glucose, echocardiography with the assessment of the left ventricle hypertrophy (LVH), ultrasound study of carotid arteries (intima-media complex thickness — CIM, and atherosclerotic plaques), vascular rigidity assessment, anklebrachial index, albumin concentration in single portion of urine at both stages of observation.

Results. While performing multiple logistic regression, presence of arterial hypertension (AH) associated with increased probability of LVH, thickening of CIM and higher vessel rigidity in standardization by gender and age. Relation of MS with the markers of TOD has not been found. In 2 years of follow-up there was a significant increase of patients with thickening of CIM (from 81 (24,5%) to 146 (44,1%), p<0,001) and decrease of LVH prevalence (from 154 (46,7%) to 109 (32,9%), p=0,003) together with significant decrease of BP and total cholesterol.

Conclusion. Presence of AH is associated with higher probability of LVH and increased vessel rigidity, as atherosclerotic changes in carotid arteries. MS was not related with an increased prevalence of TOD, and the main predetermining factors for structural heart abnormalities, the vessels and kidneys, were gender and age. In 2 years of observation there was markedly decreased number of patients with LVH and kidney dysfunction at the background of BP pattern improvement, and increase of the number of patients with thicker CIM, regardless of a decrease of the hypercholesterolemia patients. In MS patients there was more common to use antihypertension treatments, that led to more prominent LVH regression.

1. Redon J, Cifkova R, Laurent S, et al. Scientific Council of the European Society of Hypertension. A the metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008;26:1891e900.

2. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006; 119: 812-9.

3. Cuspidi C, Facchetti R, Bombelli M et al Differential Value of Left Ventricular Mass Index and Wall Thickness in Predicting Cardiovascular Prognosis: Data From the PAMELA Population.Am J Hypertens. 2014; 27(8): 1079-86.

4. Scuteri A, Najjar SS, Orru’ M, et al. The central arterial burden of the metabolic syndrome is similar in men and women: the SardiNIA Study. Eur Heart J 2010; 31: 602e13.

5. Mule G, Nardi E, Cottone S, et al. Influence on metabolic syndrome on hypertensionrelated target organ damage. Journal of Internal Medicine. 2005; 257: 503-13.

6. Shlyakhto EV, Konradi AO, Rotar OP, Solntsev VN. About criteria of metabolic syndrome: importance for prevalence assessment Arterial Hypertension. 2009; 15(4): 409-12. Russian (Шляхто Е. В., Конради А.О, Ротарь О. П., Солнцев В. Н. К вопросу о критериях метаболического синдрома. Значение выбора критерия для оценки распространенности Артериальная гипертензия 2009; 15(4): 409-12).

7. Alberti KG, Eckel RH, Grundy SM, et al Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120(16): 1640-5.

8. Rotar OP, Boiarinova MA, Moguchaia EV, et al. Metabolic syndrome as claster or individual components are associated with subclinical target-organs damage in mentally working employers? Arterial Hypertension. 2015; 21 in print. Russian (Ротарь О. П., Бояринова М. А., Могучая Е. В., и др. Метаболический синдром или только его компоненты ассоциируются с субклиническим поражением органов-мишеней у работников умственного труда? Артериальная гипертензия 2015; 21 в печати).

9. Laurent S, Cockcroft J, Van Bortel L, et al European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-605.

10. Gori M, Lam CS, Gupta DK, et al PARAMOUNT Investigators Sex-specific cardiovascular structure and function in heart failure with preserved ejection fraction. Eur J Heart Fail. 2014; 16(5): 535-42.

11. Eguchi K, Schwartz JE, Roman MJ, et al. Metabolic syndrome less strongly associated with target organ damage than syndrome components in a healthy, working population. J Clin Hypertens (Greenwich). 2007; 9(5): 337-44.

12. Ishizaka N, Ishizaka Y, Hashimoto H, et al Metabolic syndrome may not associate with carotid plaque in subjects with optimal, normal, or high-normal blood pressure. Hypertension. 2006; 48(3): 411-7.

13. M. E. Safar, F. Thomas, J. Blacher, et al. Metabolic syndrome and age-related progression of aortic stiffness J Am Coll Cardiol. 2006; 47: 72-5

14. Scuteri A, Cunha PG, Rosei EA. et al MARE Consortium. Arterial stiffness and influences of the metabolic syndrome: a cross-countries study. Atherosclerosis. 2014; 233(2): 654-60.

15. Weber F. Risk factors for subclinical carotid atherosclerosis in healthy men. Neurology. 2002; 59(4): 524-8.

16. Mancia G, Carugo S, Grassi G, et al Prevalence of left ventricular hypertrophy in hypertensive patients without and with blood pressure control: data from the PAMELA population. Pressioni Arteriose Monitorate E Loro Associazioni. Hypertension. 2002; 39(3): 744-9.

17. Simpson HJ, Gandy SJ, Houston JG, et al Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass Heart 2010; 96: 148-52.

18. Gomez-Marcos MA, Recio-Rodríguez JI, Patino-Alonso MC, et al Yearly evolution of organ damage markers in diabetes or metabolic syndrome: data from the LOD-DIABETES study. Cardiovasc Diabetol. 2011; 10: 90.